Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Arthritis and Rheumatism|February 12, 2004
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trialEdward C Keystone, Michael H Schiff, Joel M Kremer, et al.
Arthritis and Rheumatism|June 10, 2004
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditionsMichael H Schiff, Gino DiVittorio, John Tesser, et al.
Arthritis and Rheumatism|June 26, 2008
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled studyMichael E Weinblatt, Michael H Schiff, Eric M Ruderman, et al.
The Journal of Rheumatology|May 17, 2011
Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJoseph A Markenson, Allan Gibofsky, William R Palmer, et al.
The Journal of Rheumatology|October 19, 2010
Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registriesAllan Gibofsky, William R Palmer, Edward C Keystone, et al.
The Journal of Rheumatology|January 14, 2004
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)Daniel E Furst, Michael H Schiff, Roy M Fleischmann, et al.
Annals of the Rheumatic Diseases|February 28, 2018
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 studyPeter C Taylor, Michael H Schiff, Qingmin Wang, et al.
Drugs & Aging|March 16, 2006
Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studiesMichael H Schiff, Elaine B Yu, Michael E Weinblatt, et al.
The Journal of Rheumatology. Supplement|February 6, 2009
Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidenceStanley B Cohen, Marc D Cohen, John J Cush, et al.
The Journal of Rheumatology|March 17, 2006
Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experienceLarry W Moreland, Michael E Weinblatt, Edward C Keystone, et al.
Pageof 4